Acquisition Opportunity Bellevue Compounding Pharmacy was acquired in late 2020 by Hartig Drug Company, suggesting a potential cross-sell of robust compounding capabilities, specialty formulations, and distribution services to Hartig’s existing customer base and pharmacy network.

Specialty Focus As one of the country’s largest specialty pharmacies with PCAB accreditation and a Center of Excellence designation, there is a compelling upsell case for advanced sterile and non-sterile compounding services, personalized patient support programs, and partner-facing training for physicians and clinics.

Tech & Digital The tech stack includes modern web and media integrations (WordPress, oEmbed, YouTube) and HTTP/3 support, signaling readiness for enhanced digital engagement, patient portals, secure messaging, and digital marketing collaborations to expand patient outreach and education.

Market Position With revenue in the mid seven-figure range and a 51-200 employee base, Bellevue Pharmacy sits between mid-market independents and large national chains, presenting opportunities to offer scalable outsourcing, joint marketing, and white-label patient services to mid-sized networks seeking specialty services.

Strategic Growth Recent consolidation under Hartig implies a potential for channel partnerships, preferred supplier agreements, and integration of Bellevue’s bespoke pharmacy solutions into larger retirement, long-term care, or specialty clinics portfolios seeking high-touch, patient-centric care.